Funding Rounds
Pharvaris Series C (2020, $80M)
PharvarisClinical stage developer focused on providing an oral treatment for patients using a bradykinin B2 receptor antagonist.
Summary
Stage: Series C
Raised Amount: $80.00M
Raised Date: 2020-01-01
Stage: Series C
Raised Amount: $80.00M
Raised Date: 2020-01-01